You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》汇丰研究上调昊海生物科技(06826.HK)目标价至99元 评级「买入」
阿思达克 05-31 10:42
汇丰研究发表报告,料昊海生物科技(06826.HK)今年迎来强劲复苏,2020至2023年收入与纯利年复合增长率料分别达25%及38%,认为受惠其眼科产品带动。在收购Juva後,在持续整合医美2B及2C销售渠道下,料市务推广迎来潜在协同效应。不过其目前估值相当於明年预测市盈率19倍,对比医疗仪器同期的35倍,认为昊海生物在眼科的领导地位及与Juva的协同效应尚未被市场完全认识。

该行表示,公司在医美市场方面很好的定位,且正扩大其产品线,包括3款不同定价的玻尿酸产品、收购Juva与投资Eirion後,公司亦进入设备与肉毒杆菌素业务。

汇丰下调昊海生物今年收入及纯利预测31%及45%,以反映疫情对公司的负面影响;并修改估值计算方法,由市盈率改为现金流折现率为基础,以更好反映公司长远增长潜力。该行维持对昊海生物「买入」评级,目标价由57.8元升至99元,相当於明年预测市盈率30倍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account